Skip Navigation


The global source of news, directories, proprietary market research, and analysis for clinical trials professionals and patients.

Bookmark | Print | E-Mail

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic e-mail notifications as soon as a clinical trial is posted in the medical category you're interested in.






Home » Drug Information » FDA-Approved Drugs » 1998
Medical Areas: Endocrinology | Musculoskeletal | Obstetrics/Gynecology

View By: Year Company Therapeutic Areas Drug Names 

Drug Information

The following information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Drug Name: Estratab (.3 mg )

Company: Solvay Pharmaceuticals
Approval Status: Approved March 1998
Treatment Area: prevention of osteoporosis

General Information

Estratab (.3 mg ) has been approved for the prevention of osteoporosis.

Clinical Results

In a two-year clinical trial, women on .3 mg Estratab tablets showed increased bone mineral density over baseline in the spine, hip, and whole body.

Side Effects

Women taking this low dose also experienced fewer side effects, such as headache, nausea, breast tenderness, and vaginal bleeding, than women on higher doses.


Jobson Medical Information

Copyright © 1995-2009 Jobson Medical Information LLC.


Designed by Piehead Productions LLC.